Astatine-211-labelled antibody OKT10-B10 targets CD45 on several haematological malignancies and is being tested in patients with multiple myeloma, myelodysplastic syndrome, and several types of acute leukaemia, as well as a conditioning method before hematopoietic stem cell transplantation in non-malignant conditions to reduce graft rejection [100,101]. Here, PTPRC is linked to plasma cell myeloma.